Form 4 Immunovant, Inc. For: Dec 02 Filed by: Pande Atul
Immunovant, Inc. (IMVT)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant, Inc. (NASDAQ: IMVT) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.MarketBeat
- Immunovant price target lowered to $45 from $47 at Wells Fargo [Yahoo! Finance]Yahoo! Finance
- We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Immunovant, Inc. (NASDAQ: IMVT) had its price target lowered by analysts at Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.MarketBeat
- FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 8/6/24 - Miss
IMVT
Sec Filings
- 12/18/24 - Form 4
- 12/18/24 - Form 3
- 12/4/24 - Form 4
- IMVT's page on the SEC website